India And China Not Yet Major Sites For FDA-Regulated Trials, Parexel Finds
This article was originally published in PharmAsia News
Executive Summary
While India now ranks among the top 10 countries conducting FDA-regulated clinical trials, it has yet to see a major influx of trial work
You may also be interested in...
R&D Outsourcing Reaches Tipping Point As More Firms Do Most Trials Overseas
Five years ago, Wyeth hit a roadblock in developing the intravenous antibiotic Tygacil (tigecyline) - not enough patients were enrolling in its Phase III trial
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).